News out today on IPIX regarding another very successful P2 trial result. 4 for 4 verticals without a hiccup. IMHO by far the most dynamic yet undervalued Micro-cap Biotech in discussions with BP.
Also under the radar is independent research study on Kevetrin P54 modulation for treatment of AML, very positive. Poster Title: “Kevetrin: Preclinical Study of a New Compound in Acute Myeloid Leukemia”